TRAWNasdaqPharmaceutical PreparationsFiscal year ends December 31
Traws Pharma, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.37−0.00 (-0.76%)
Close on Oct 19, 2026
- Market cap
- $5.81M
- P/E (TTM)
- 0.4
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
40.1%
6M of 15M shares
Institutional holders
34
13 new, 7 sold out
Net institutional buying
3M
In Q2 2026
Insider trades, 12 months
1 buys · 0 sales
Net bought $998.21K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Joseph Edelman | 979,815 | 6.10% | 13G (passive) amendment | Mar 31, 2026 |
| Perceptive Advisors LLC | 886,887 | 9.99% | 13G (passive) amendment | Sep 30, 2025 |
| Neil Shahrestani | 812,524 | 9.99% | 13G (passive) amendment | Dec 31, 2025 |
| Orbimed Advisors LLC | 760,824 | 19.90% | 13D (active) amendment | Dec 31, 2024 |
| Phillip Gross | 730,000 | 9.14% | 13G (passive) | Dec 31, 2025 |
| Squadron Master Fund LP | 713,540 | 8.90% | 13G (passive) amendment | Dec 31, 2025 |
| Alex Silverstein | 6,565,474 | 9.90% | 13G (passive) | Jun 30, 2026 |
| Squadron Capital Management LLC | 591,000 | 8.40% | 13G (passive) amendment | Sep 30, 2025 |
| Perceptive Life Sciences Master Fund, Ltd. | 545,197 | 9.99% | 13G (passive) amendment | Mar 31, 2025 |
| Chernett Jorey | 543,268 | 6.80% | 13G (passive) | Jan 14, 2026 |
| Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B | 403,650 | 9.90% | 13G (passive) | Dec 31, 2024 |
| Adage Capital Management, L.P. | 330,000 | 6.50% | 13G (passive) | Mar 31, 2025 |
| Alyeska Investment Group, L.P. | 302,252 | 9.90% | 13G (passive) | Dec 31, 2024 |
| Nikolay Savchuk | 2,934,525 | 11.60% | 13D (active) | Apr 1, 2024 |
| OrbiMed Capital GP VIII LLC | 1,876,198 | 11.90% | 13D (active) amendment | Apr 16, 2026 |
| Ikarian Capital, LLC | 1,555,423 | 9.50% | 13G (passive) amendment | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of TRAW | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Orbimed Advisors LLC | 1,203,260 | 7.83% | $1.01M | +597,729 | 0.02% |
| Ally Bridge Group (NY) LLC | 786,236 | 5.12% | $663.03K | New | 0.59% |
| Adage Capital Partners Gp, L.L.C. | 730,000 | 4.75% | $615.61K | – | 0.00% |
| ADAR1 Capital Management, LLC | 597,729 | 3.89% | $504.07K | +443,631 | 0.02% |
| Lynx1 Capital Management LP | 559,470 | 3.64% | $471.80K | +544,392 | 0.05% |
| Ikarian Capital, LLC | 478,142 | 3.11% | $403.22K | −200,000 | 0.04% |
| Sphera Funds Management Ltd. | 398,486 | 2.59% | $336.04K | New | 0.04% |
| Vanguard Capital Management LLC | 330,049 | 2.15% | $278.23K | +274,856 | 0.00% |
| Jane Street Group, LLC | 216,006 | 1.41% | $182.16K | +194,765 | 0.00% |
| Alyeska Investment Group, L.P. | 164,376 | 1.07% | $138.62K | New | 0.00% |
| Boothbay Fund Management, LLC | 133,936 | 0.87% | $112.95K | −60,600 | 0.00% |
| Geode Capital Management, LLC | 111,365 | 0.72% | $93.92K | +34,262 | 0.00% |
| Hrt Financial LP | 91,220 | 0.59% | $76 | New | 0.00% |
| Kynam Capital Management, LP | 84,400 | 0.55% | $71.18K | New | 0.00% |
| Dauntless Investment Group, LLC | 80,574 | 0.52% | $67.95K | −336,424 | 0.05% |
| Vanguard Fiduciary Trust Co | 54,511 | 0.35% | $45.95K | +22,707 | 0.00% |
| Northern Trust Corp | 37,454 | 0.24% | $31.59K | New | 0.00% |
| State Street Corp | 25,802 | 0.17% | $21.76K | – | 0.00% |
| XTX Topco Ltd | 18,092 | 0.12% | $15.26K | New | 0.00% |
| SG Americas Securities, LLC | 14,524 | 0.09% | $12 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 34 | 6M | 40.1% | 13 / 9 | 8 / 7 | 4M | 1M |
| Q1 2026 | 28 | 4M | 23.6% | 14 / 2 | 4 / 7 | 1M | 0M |
| Q4 2025 | 22 | 3M | 22.2% | 9 / 6 | 2 / 5 | 2M | 0M |
| Q3 2025 | 18 | 1M | 8.5% | 3 / 6 | 1 / 4 | 0M | 0M |
| Q2 2025 | 19 | 1M | 8.2% | 4 / 2 | 5 / 3 | 0M | 1M |
| Q1 2025 | 18 | 2M | 11.3% | 3 / 8 | 4 / 3 | 1M | 0M |
| Q4 2024 | 18 | 1M | 7.6% | 9 / 3 | 2 / 2 | 1M | 0M |
| Q3 2024 | 11 | 1M | 4.2% | 11 / 0 | 0 / 0 | 1M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of TRAW | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 177,200 | 1.15% | $149.43K | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 152,849 | 0.99% | $128.90K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 39,339 | 0.26% | $57.43K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 8,098 | 0.05% | $11.82K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 7,466 | 0.05% | $10.90K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 743 | 0.00% | $1.08K | 0.00% | May 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | 11 | 0.00% | $9 | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Nikolay Savchuk | Chief Operating Officer, Director | 1,795,706 | 11.68% | Jul 15, 2026 |
| Iain D. Dukes | Chief Executive Officer, Director | 1,816,230 | 11.82% | Jul 14, 2026 |
| Charles David Pauza | Chief Science Officer Virology | 115,971 | 0.75% | Jul 16, 2026 |
| Robert Redfield | Chief Medical Officer | 113,919 | 0.74% | Jul 14, 2026 |
| Charles Nolan Parker | Chief Financial Officer | 15,393 | 0.10% | Jul 14, 2026 |
| Mark Patrick Guerin | Chief Financial Officer | 39,255 | 0.26% | Feb 10, 2025 |
| Nora Brennan | Interim CFO | – | – | Feb 7, 2025 |
| Werner Cautreels | Director | 109,222 | 0.71% | Jul 15, 2026 |
| Jack E. Stover | Director | 6,165 | 0.04% | Jul 14, 2026 |
| Mary Teresa Shoemaker | Director | 6,292 | 0.04% | Jul 14, 2026 |
| Trafford Clarke | Director | 6,157 | 0.04% | Jul 14, 2026 |
| John Harold Leaman | Director | 4,058 | 0.03% | Jul 14, 2026 |
| Advisors Llc Orbimed | 10% owner | – | – | Apr 28, 2026 |
| Capital GP VIII LLC OrbiMed | 10% owner | 1,203,250 | 7.83% | Apr 28, 2026 |
| Tpav, Llc | 10% owner | 1,222,738 | 7.96% | Apr 8, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Capital GP VIII LLC OrbiMed 10% owner | Apr 16, 2026 | Buy | +597,729 | $1.67 | $998.21K | 1,203,250 |
| Charles Nolan Parker Chief Financial Officer | Dec 12, 2025 | Award | +15,393 | – | – | 15,393 |
| Iain D. Dukes Chief Executive Officer, Director | Dec 12, 2025 | Award | +36,943 | – | – | 171,130 |
| Jack E. Stover Director | Dec 12, 2025 | Award | +6,157 | – | – | 6,165 |
| Nikolay Savchuk Chief Operating Officer, Director | Dec 12, 2025 | Award | +16,419 | – | – | 150,606 |
| Charles David Pauza Chief Science Officer Virology | Dec 12, 2025 | Award | +18,471 | – | – | 115,971 |
| John Harold Leaman Director | Dec 12, 2025 | Award | +4,058 | – | – | 4,058 |
| Robert Redfield Chief Medical Officer | Dec 12, 2025 | Award | +16,419 | – | – | 113,919 |
| Trafford Clarke Director | Dec 12, 2025 | Award | +6,157 | – | – | 6,157 |
| Mary Teresa Shoemaker Director | Dec 12, 2025 | Award | +6,157 | – | – | 6,292 |
| Werner Cautreels Director | Dec 12, 2025 | Award | +4,874 | – | – | 109,222 |
| Nikolay Savchuk Chief Operating Officer, 10% owner | Apr 2, 2025 | Other | −605,531 | – | – | 0 |
| Werner Cautreels Chief Executive Officer, Director | Feb 18, 2025 | Option exercise | +96,348 | $0.01 | $963 | 104,348 |
| Mark Patrick Guerin CFO | Jun 18, 2024 | Tax withholding | −2,221 | $0.47 | $1.04K | 39,255 |
| Mark Patrick Guerin CFO | Jun 10, 2024 | Option exercise | +5,500 | – | – | 41,476 |
| Iain D. Dukes Executive Chairman, Director | Apr 1, 2024 | Award | +67,500 | – | – | 134,187 |
| Nikolay Savchuk Chief Operating Officer, Director | Apr 1, 2024 | Award | +67,500 | – | – | 134,187 |
| Robert Redfield Acting Chief Medical Officer | Apr 1, 2024 | Award | +97,500 | – | – | 97,500 |
| Nikolay Savchuk Chief Operating Officer, Director | Apr 1, 2024 | Award | +67,550 | – | – | 134,187 |
| Nikolay Savchuk Chief Operating Officer, Director | Apr 1, 2024 | Award | +66,687 | – | – | 66,687 |
| Nikolay Savchuk Chief Operating Officer, Director | Apr 1, 2024 | Award | +1,645,100 | – | – | 1,645,100 |
| Nikolay Savchuk Chief Operating Officer, Director | Apr 1, 2024 | Award | +885,532 | – | – | 885,532 |
| Werner Cautreels Chief Executive Officer, Director | Apr 1, 2024 | Award | +200,000 | – | – | 200,000 |
| Iain D. Dukes Executive Chairman, Director | Apr 1, 2024 | Award | +66,687 | – | – | 66,687 |
| Iain D. Dukes Executive Chairman, Director | Apr 1, 2024 | Award | +67,550 | – | – | 134,187 |
| Iain D. Dukes Executive Chairman, Director | Apr 1, 2024 | Award | +1,645,100 | – | – | 1,645,100 |
| Charles David Pauza Chief Science Officer Virology | Apr 1, 2024 | Award | +97,500 | – | – | 97,500 |
| Mark Patrick Guerin CFO AND COO | Mar 14, 2024 | Tax withholding | −2,591 | $0.90 | $2.33K | 35,976 |
| Steven M. Fruchtman PRESIDENT, CHIEF EXECUTIVE OFF, Director | Mar 14, 2024 | Tax withholding | −8,727 | $0.90 | $7.85K | 74,792 |
| Mark Patrick Guerin CFO AND COO | Mar 13, 2024 | Option exercise | +8,666 | – | – | 38,567 |
| Steven M. Fruchtman PRESIDENT, CHIEF EXECUTIVE OFF, Director | Mar 13, 2024 | Option exercise | +23,111 | – | – | 83,519 |
| Steven M. Fruchtman PRESIDENT, CHIEF EXECUTIVE OFF, Director | Feb 7, 2024 | Option exercise | +21,320 | – | – | 69,620 |
| Steven M. Fruchtman PRESIDENT, CHIEF EXECUTIVE OFF, Director | Feb 7, 2024 | Tax withholding | −9,212 | $0.67 | $6.17K | 60,408 |
| Mark Patrick Guerin CFO AND COO | Feb 7, 2024 | Option exercise | +6,900 | – | – | 32,344 |
| Mark Patrick Guerin CFO AND COO | Feb 7, 2024 | Tax withholding | −2,443 | $0.67 | $1.64K | 29,901 |
| Mark Patrick Guerin CFO AND COO | Aug 3, 2023 | Tax withholding | −1,422 | $1.02 | $1.45K | 25,444 |
| Steven M. Fruchtman PRESIDENT, CHIEF EXECUTIVE OFF, Director | Aug 3, 2023 | Tax withholding | −4,744 | $1.01 | $4.79K | 48,300 |
| Mark Patrick Guerin CFO AND COO | Aug 2, 2023 | Option exercise | +4,750 | – | – | 26,866 |
| Steven M. Fruchtman PRESIDENT, CHIEF EXECUTIVE OFF, Director | Aug 2, 2023 | Option exercise | +12,567 | – | – | 53,044 |
| Mark Patrick Guerin CFO AND COO | Jun 12, 2023 | Tax withholding | −1,575 | $1.14 | $1.80K | 22,116 |
| Mark Patrick Guerin CFO AND COO | Jun 12, 2023 | Option exercise | +5,500 | – | – | 23,691 |
| Mark S. Gelder MD CHIEF MEDICAL OFFICER | Feb 7, 2023 | Option exercise | +5,833 | – | – | 11,729 |
| Mark S. Gelder MD CHIEF MEDICAL OFFICER | Feb 7, 2023 | Tax withholding | −1,242 | $1.36 | $1.69K | 10,487 |
| Steven M. Fruchtman PRESIDENT, CHIEF EXECUTIVE OFF, Director | Feb 7, 2023 | Tax withholding | −6,977 | $1.36 | $9.49K | 40,477 |
| Steven M. Fruchtman PRESIDENT, CHIEF EXECUTIVE OFF, Director | Feb 7, 2023 | Option exercise | +21,320 | – | – | 47,454 |
| Mark Patrick Guerin CFO AND COO | Feb 7, 2023 | Option exercise | +6,900 | – | – | 19,976 |
| Mark Patrick Guerin CFO AND COO | Feb 7, 2023 | Tax withholding | −1,785 | $1.36 | $2.43K | 18,191 |
| Mark S. Gelder MD CHIEF MEDICAL OFFICER | Aug 3, 2022 | Tax withholding | −1,135 | $1.32 | $1.50K | 5,896 |
| Mark Patrick Guerin CFO AND COO | Aug 3, 2022 | Tax withholding | −1,355 | $1.32 | $1.79K | 13,076 |
| Steven M. Fruchtman PRESIDENT, CHIEF EXECUTIVE OFF, Director | Aug 3, 2022 | Tax withholding | −4,562 | $1.32 | $6.02K | 26,134 |
| Mark S. Gelder MD CHIEF MEDICAL OFFICER | Aug 2, 2022 | Option exercise | +4,650 | – | – | 7,031 |
| Mark Patrick Guerin CFO AND COO | Aug 2, 2022 | Option exercise | +4,750 | – | – | 14,431 |
| Steven M. Fruchtman PRESIDENT, CHIEF EXECUTIVE OFF, Director | Aug 2, 2022 | Option exercise | +12,566 | – | – | 30,696 |
| Abraham N. Oler SVP Corp Dev & Gen Counsel | Jan 28, 2022 | Buy | +1,500 | $1.67 | $2.51K | 24,514 |
| Abraham N. Oler SVP Corp Dev & Gen Counsel | Jan 21, 2022 | Buy | +1,500 | $2.02 | $3.03K | 23,014 |
| Abraham N. Oler SVP CORP DEV & GEN COUNSEL | Jan 14, 2022 | Buy | +1,500 | $2.20 | $3.30K | 21,514 |
| Abraham N. Oler SVP Corp Dev & Gen Counsel | Jan 7, 2022 | Buy | +1,500 | $2.39 | $3.59K | 20,014 |
| Abraham N. Oler SVP CORP DEV & GEN COUNSEL | Nov 19, 2021 | Buy | +1,000 | $3.16 | $3.16K | 18,514 |
| Abraham N. Oler SVP Corp Dev & Gen Counsel | Nov 18, 2021 | Option exercise | +5,000 | $3.00 | $15.00K | 17,514 |
| Abraham N. Oler SVP Corp Dev & Gen Counsel | Sep 28, 2021 | Buy | +2,381 | $4.20 | $10.00K | 12,515 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| M. Fruchtman Steven Officer, Director | Mar 14, 2024 | 8,727 | $7.86K | Mar 14, 2024 | Restricted stock vesting under a registered plan |
| Guerin Mark Officer | Mar 14, 2024 | 2,591 | $2.33K | Mar 14, 2024 | Restricted stock vesting under a registered plan |
| M. Fruchtman Steven Officer, Director | Feb 8, 2024 | 9,212 | $6.17K | Feb 8, 2024 | Restricted stock vesting under a registered plan |